Commodore Capital LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.29B2026 Q3
Positions37
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.65.2%
What Changed This Quarter?
Top Holdings
RLAY
Relay Therapeutics
16.8%
ELVN
Enliven Therapeutics
11.6%
ALKS
Alkermes
9.0%
ANRO
Alto Neuroscience
5.4%
SYRE
Spyre Therapeutics
4.8%
AMLX
Amylyx Pharmaceuticals
4.5%
LBRX
LB Pharmaceuticals
3.8%
DMRA
Damora Therapeutics
3.2%
New / Increased
11 new · 2 increased
DMRANEW
Damora Therapeutics
3.2%
SRZNNEW
Surrozen
2.2%
KRSANEW
Korsana Biosciences
2.2%
SGMTNEW
Sagimet Biosciences
2.1%
ADRXNEW
Adarx Pharmaceuticals
1.9%
IFRX
Inflarx
1.3%
+27.0%
RLMD
Relmada Therapeutics
0.7%
+64.9%
Reduced / Exited
11 reduced · 7 sold out
AMLX
Amylyx Pharmaceuticals
4.5%
-64.6%
COGT
Cogent Biosciences
3.1%
-58.5%
DFTX
Definium Therapeutics
2.1%
-65.0%
ASMB
Assembly Biosciences
0.8%
-67.4%
PHVS
N.V. Pharvaris
2.3%
-35.1%
TNGXEXIT
Tango Therapeutics
4.2%
EYPTEXIT
Eyepoint
3.9%
Damora Therap…EXIT
Damora Therapeutics
3.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.